Navigation Links
Versus Technology Announces Third Quarter Results
Date:8/28/2008

TRAVERSE CITY, Mich., Aug. 28 /PRNewswire-FirstCall/ -- Versus Technology, Inc. ("Versus" or the "Company") announced revenues of $1,176,000 for its third fiscal quarter ended July 31, 2008, a decrease of 8% compared to revenues of $1,283,000 for the same quarter of the prior year. Revenues for the nine months ended July 31, 2008, were $4,026,000, compared to $3,554,000 for the nine months ended July 31, 2007, a 13% increase. Versus' quarterly revenues can vary significantly depending on the timing and delivery of major customer projects. Accordingly, revenues reported in any one quarter are not necessarily indicative of what full year results will be.

Gross profits as a percentage of revenues were 71% for the current year's third quarter compared to 69% for the same quarter of the prior year. Operating expenses, other than cost of revenues, increased 25% for the current year's third quarter compared to the same quarter of the prior year, due primarily to an increase in research and development and sales and marketing expenses.

Versus reported a net loss of $448,000 for the current year's third quarter compared to a net loss of $134,000 for the same quarter of the prior year. The Company reported a net loss of $825,000 for the nine months ended July 31, 2008, compared to a net loss of $544,000 for the nine months ended July 31, 2007.

For additional information, please refer to the attached unaudited consolidated financial statements.

Versus Technology, Inc. (Pink Sheets: VSTI.PK) ( http://www.versustech.com ) (Versus) is the leader in the development and sale of context-aware systems used for the management of patient flow and medical assets and to improve caregiver/patient communications in medical and long-term care facilities. Versus also supplies Active RFID/IR tags and readers that make locating systems more precise, security systems more intelligent, data collection routin
'/>"/>

SOURCE Versus Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Versus Technology Announces Fourth Quarter Results
2. Smart Home Cleaning: New Web Site Educates Consumers on Looking Clean Versus Being Clean
3. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
4. Versus Technology Announces First Quarter Results
5. Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006
6. Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model
7. Eat Well, Save Money: BJs Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices
8. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
9. Quantum light beams good for fast technology
10. New Smart Technology Makes Patient Data Collection Easier, More Efficient
11. Align Technology Executive to Present at Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... A US Airman, fresh from basic training...leukemia patient whose life he saved by donating h...san Air Base, Republic of Korea (PRWEB) November 2...Airman whose blood donation saved her life, met fo...Nov. 21, 2008. , , , , ,Airman Tamarias Pope, 8th...
(Date:11/21/2008)...g of shareholders to be held on January 8, 2009 ,... Med-Emerg International Inc. ("MedEmerg") (OTCBB:...h services, announced today that it has obtained a... Justice concerning its previously announced plan ...ch AIM Health Group Inc. ("AIM") will acquire all ...
(Date:11/21/2008)...., Nov. 21 Heska Corpora...esent at the New York Society of,Security Analyst...ence on,December 2, 2008 at 1177 Avenue of the Am...on is scheduled to begin at 9:35 a.m. Eastern Time...via live webcast and for two weeks,following the ...
(Date:11/21/2008)...Banzel proved effective against Lennox-Gastaut syn...s) -- A new drug called Banzel (rufinamide) has be...ere form of epilepsy called Lennox-Gastaut syndrom... Friday. , The approval was based on results of...s ages 4 to 30. Compared to patients who took a pl...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...study shows a clear link between fast food consump...sting that // fast food increases the risk of obes...the association between reported fast food habits ...insulin resistance over 15 years. The diets of mor...
...nk between migraines and the risk of coronary hear...t study shows // no link between the two but does ...est pain, also known as angina. People with a hist... aura -- seeing what appears to be spots or lines ...
...t form of macular degeneration represents about 10...lated macular degeneration is the leading cause of...rs of age and older. // Two new studies show a the...n effective treatment for age-related, "wet" macul...
..., more intense physical activity can help maintain...rchers according to // a new study. For the study ...1900 and 1920 from the Finland, Italy, and Netherl...ty of physical activities of the participants was ...
Other Medicine News:
(Date:11/20/2008).... 20 PAREXEL Internation... biopharmaceutical services provider, today announ...provide regulatory consulting and clinical researc...ce, PAREXEL now has locations throughout five impo...which also include Argentina, Brazil, Chile, and M...
(Date:11/19/2008)...ientists report basic findings on critical enzyme,...better treat an array of disorders , , MEMP...ientists at St. Jude Children,s Research Hospital ... the body,s enzyme workhorses called calpains. ,...lpains function in many cellular processes, includ...
(Date:11/18/2008)...christmasseals.org to learn more, make a donation...NGTON, Nov. 17 Millions...th, courtesy of the American Lung Association. The... fundraising tradition dating back to 1907 when th...osis. , , "Most Americans alive today hav...
(Date:11/13/2008)..., Mass., Nov. 13 Hologic...facturer and supplier of premium,diagnostics, medi...d to,serving the healthcare needs of women, today ...k pivotal clinical trial. The Cervista HPV high-ri...e U.S. and is expected to be,launched in the Europ...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4PhoneTree Announces New Patient Messaging Product and Pricing Options 4660 1Roper Industries Announces Record Third Quarter Results 4657 1Roper Industries Announces Record Third Quarter Results 4657 2Roper Industries Announces Record Third Quarter Results 4657 3Roper Industries Announces Record Third Quarter Results 4657 4Roper Industries Announces Record Third Quarter Results 4657 5Roper Industries Announces Record Third Quarter Results 4657 6Roper Industries Announces Record Third Quarter Results 4657 7Roper Industries Announces Record Third Quarter Results 4657 8Roper Industries Announces Record Third Quarter Results 4657 9Roper Industries Announces Record Third Quarter Results 4657 10Male Drivers are Hitting Killing Most Child Pedestrians New Study Shows 4654 1Male Drivers are Hitting Killing Most Child Pedestrians New Study Shows 4654 2Male Drivers are Hitting Killing Most Child Pedestrians New Study Shows 4654 3California Association of Marriage 26 Family Therapists Offers Tips on How to Cope With a Traumatic Event 4651 1California Association of Marriage 26 Family Therapists Offers Tips on How to Cope With a Traumatic Event 4651 2
... at International Conference on Antiviral,Research...- ADVENTRX,Pharmaceuticals, Inc. , a biopharmaceut...ommercializing proprietary product,candidates for ...nnounced today that it presented results demonstra...influenza (bird flu) viruses when,the Company,s br...
...Plus Minocycline Showed Substantial,Reduction of D...Remitting Multiple Sclerosis , Combination Treatme...nd Was Well Tolerated , KANSAS CITY, Mo, May 4, 20...y showed that a combination of Copaxone,(glatirame...c,minocycline reduced T1 Gadolinium (Gd)-enhancing...
Other Medicine Technology:ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 2ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12
Needle holder, delicate, curved without lock
Rhoton microscopic forceps, straight
Microscopic scissors, curved
Our unique velcro design apron with elasticized back panels for additional support and comfort. Shoulder pads are a standard. Shoulder drop-away optional.
Medicine Products: